ABSTRACT
AIM:
To investigate the effect of
adalimumab combined with
dexamethasone intravitreal implant in the
treatment of refractory non-infectious
uveitis macular edema(UME).
METHODS:
A total of 92 cases(131
eyes)of refractory non-infectious UME
patients admitted to our
hospital from January 2020 to January 2022 were selected and randomly divided into
control group, with 46 cases(63
eyes)treated with
dexamethasone intravitreal implant and
observation group, with 46 cases(68
eyes)treated with
adalimumab subcutaneous injection combined with
dexamethasone intravitreal implant. The best corrected
visual acuity(BCVA), central
retinal thickness(CRT), vitreous opacity and Th17/Treg
cytokines were measured before and
after treatment, and the occurrence of adverse reactions was recorded.
RESULTS:
Totally 3 cases(4
eyes)were
lost to follow-up.
After treatment for 1, 3, 6 and 12 mo, BCVA was improved in both groups compared with that before
treatment, and CRT, vitreous opacity score,
serum interleukin(IL)-17 and
IL-22 levels were decreased compared with those before
treatment, and
serum transforming growth factor-β(TGF-β)and
IL-10 levels were increased compared with those before
treatment. BCVA in the
observation group was better than that in the
control group, and CRT, vitreous opacity score,
serum IL-17 and
IL-22 levels were lower than those in the
control group, and
serum TGF-β and
IL-10 levels were higher than those in the
control group(all P<0.05). During
treatment and follow-up, no serious adverse reactions occurred in both groups.
CONCLUSION:
Adalimumab combined with
dexamethasone intravitreal implants in the
treatment of refractory non-infectious UME can significantly subside the
macular edema, reduce vitreous opacity and improve
visual acuity.